---
document_datetime: 2024-11-21 15:34:40
document_pages: 26
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bydureon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: bydureon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 16.719654
conversion_datetime: 2025-12-20 16:07:24.602791
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Bydureon

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0081              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 20/11/2024                          |                                             | SmPC and PL                      |           |
| IB/0079              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 11/04/2024                          | 24/07/2024                                  | SmPC and PL                      |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IAIN/0078/G   | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                     | 31/07/2023   | 24/07/2024   | Annex II and PL   |     |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----|
| IB/0077       | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                    | 03/05/2023   | n/a          |                   |     |
| IB/0076       | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                           | 31/10/2022   | n/a          |                   |     |
| II/0074       | Update of section 4.8 of the SmPC in order to add cholelithiasis and cholecystitis to the list of adverse drug reactions (ADRs) with frequency (uncommon) based on the cumulative review of pre-clinical and clinical study data, post-marketing data, medical/scientific literature and signal searches in internal and external databases on 'Gallbladder- related disorders' and exenatide. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC. | 14/07/2022   | 29/06/2023   | SmPC and PL       | n/a |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             |                                                                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------|
| II/0073   | Extension of indication to include the treatment of adolescents and children aged 10 years and above based on the results from Study BCB114 (D5551C00002); a phase 3, double-blind, placebo- controlled, randomized, multi-center study to assess the safety and efficacy of exenatide once weekly in adolescents with type 2 diabetes, which was initially submitted and assessed by the CHMP as part of the post-authorisation measure (PAM) P46 028. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated and the Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update the contact details of the local representatives in the Package Leaflet. Version 35.1 of the RMP was agreed during the procedure. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 22/04/2022 | 30/05/2022 | SmPC and PL | Please refer to Scientific Discussion 'Bydureon-H-C-2020- II-73' |
| IA/0075/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 03/05/2022 | n/a        |             |                                                                  |

<div style=\"page-break-after: always\"></div>

|                    | Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                       |            |            |             |                                                                                                                                                             |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9147/ 202103 | Periodic Safety Update EU Single assessment - exenatide                                                                                                                                                                                                                                                                                                                      | 28/10/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                           |
| IA/0071/G          | This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier | 22/04/2021 | n/a        |             |                                                                                                                                                             |
| PSUSA/9147/ 202003 | Periodic Safety Update EU Single assessment - exenatide                                                                                                                                                                                                                                                                                                                      | 12/11/2020 | 11/01/2021 | SmPC and PL | Please refer to exenatide PSUSA-9147-202003 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IG/1321            | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                          | 08/12/2020 | n/a        |             |                                                                                                                                                             |
| IA/0068            | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                   | 31/01/2020 | n/a        |             |                                                                                                                                                             |
| II/0067            | B.II.d.z - Change in control of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                       | 30/01/2020 | n/a        |             |                                                                                                                                                             |
| II/0066            | Update of section 4.8 of the SmPC to include                                                                                                                                                                                                                                                                                                                                 | 30/01/2020 | 11/01/2021 | SmPC,       | Drug-induced thrombocytopenia (DITP) with exenatide-                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | information about 'drug-induced thrombocytopenia (DITP)' based on spontaneous reports post- marketing and to include it as a new ADR with unknown frequency. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in line with the latest QRD template. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            | Labelling and PL       | dependent anti-platelet antibodies has been reported in the post-marketing setting. DITP is an immune-mediated reaction that is caused by drug-dependent platelet-reactive antibodies. These antibodies cause destruction of platelets in the presence of the sensitizing drug.                                                                                                                                                                                                                                                                    |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0064 | Update of sections 4.2 and 4.4 of the SmPC in order to remove the limitation of use in patients with moderate renal impairment (creatinine clearance [CrCl] 30 to 50 mL/min) based on pooled data from 8 EQW/EQWS studies undertaken in patients with mild renal impairment/chronic kidney disease stage 2 or moderate renal impairment/chronic kidney disease stage 3, and update of section 5.1 of the SmPC to include the results of a subgroup analysis from EXSCEL (Study D5551C00003/BCB109) in a subset of patients with moderate renal impairment. In addition, the MAH took the opportunity to introduce GFR as the main indicator of renal function rather than CrCl. The Package Leaflet has been updated accordingly and the MAH has taken the opportunity to implement some minor changes in the labelling. An updated RMP version 34 was provided with the application, which includes consequential changes as well as a proposal for the removal of Acute Renal | 12/12/2019 | 23/01/2020 | SmPC, Labelling and PL | The SmPC has been updated to reflect that no dose adjustment is necessary for patients with mild or moderate renal impairment and that prolonged release exenatide is not recommended for use in patients with end stage renal disease or severe renal impairment (glomerular filtration rate [GFR] < 30 mL/min). In a pre-specified subgroup analysis in EXSCEL, the HR for MACE was 0.86 (95% CI: 0.77-0.97) in patients with baseline eGFR â‰¥ 60 mL/min/1.73 m2 and 1.01 (95% CI: 0.86-1.19) in patients with baseline eGFR < 60 mL/min/1.73 m2. |

<div style=\"page-break-after: always\"></div>

|                    | on the GVP V Rev2 guidance. In addition, upon request following the assessment of II/54, a Pan EU epidemiological study to monitor events of pancreatic cancer has been included as an additional planned pharmacovigilance activity. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                       |            |     |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/9147/ 201903 | Periodic Safety Update EU Single assessment - exenatide                                                                                                                                                                                                                                                                                                                                                                                                                                       | 31/10/2019 | n/a | PRAC Recommendation - maintenance |
| IB/0065/G          | This was an application for a group of variations. B.II.g.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supporting data B.II.g.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supporting data                                                                                                                                                                                  | 19/09/2019 | n/a |                                   |
| II/0059            | Submission of the final CSR for Study H80-MC-B016; a modified Prescription-Event Monitoring Program (Modified PEM) to be conducted in the UK, enrolling patients with Type 2 diabetes mellitus, to quantify the incidence of acute pancreatitis in the first 12 months after initiating treatment with prescription exenatide once weekly. An updated RMP version 33 was provided as part of the application. The provision of the final CSR addresses Post- authorisation Measure MEA 010.5. | 11/07/2019 | n/a | n/a                               |

<div style=\"page-break-after: always\"></div>

|           | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                        |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----|
| IB/0062   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 02/07/2019 | 23/09/2019 | SmPC, Labelling and PL |     |
| II/0054   | Submission of the final study report, upon request by PRAC following the assessment of MEA 11.5, from study H8O-MC-B015 extension/ D5550R00003; 'Incidence of Pancreatic Malignancy and Thyroid Neoplasm in Type 2 Diabetes Mellitus Patients who Initiate Exenatide Compared to Other Antihyperglycemic Drugs', as well as the feasibility study 'Incidence of pancreatic cancer and thyroid neoplasm among type 2 diabetes patients who initiated Bydureon (exenatide) as compared with those who initiated other glucose lowering drugs'. An updated RMP (version 32) was agreed during the procedure. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 11/04/2019 | n/a        |                        | n/a |
| IAIN/0061 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 08/04/2019 | 23/09/2019 | Annex II and PL        |     |

<div style=\"page-break-after: always\"></div>

|           | Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------|
| IAIN/0060 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                        | 05/04/2019 | 23/09/2019 | SmPC and PL |                                                                      |
| II/0057   | Update of sections 4.8 and 5.1 of the SmPC in order to implement minor changes in line with the revised study report for the DURATION 7 study (previously assessed as part of variation II/45). In addition, the MAH took the opportunity to implement editorial changes for increased clarity in the SmPC section 6.6 and the Package Leaflet of the pre-filled pen. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data               | 14/02/2019 | 23/09/2019 | SmPC and PL | The revision did not affect the results or conclusions of the study. |
| IA/0056/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.8 - Administrative change - Changes to date of the audit to verify GMP compliance of the manufacturer of AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 10/12/2018 | n/a        |             |                                                                      |
| IAIN/0055 | C.I.1.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a Union                                                                                                                                                                                                                                                                                                                                                                                                          | 27/11/2018 | 23/09/2019 | PL          |                                                                      |

<div style=\"page-break-after: always\"></div>

|                    | referral procedure - The product is not covered by the defined scope of the procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9147/ 201803 | Periodic Safety Update EU Single assessment - exenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 31/10/2018 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0050            | Update of sections 4.1, 4.2, 4.4 and 5.1 of the SmPC based on the final CSR of study EXSCEL (EXenatide Study of Cardiovascular Event Lowering; 'A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus ') in fulfilment of LEG 009. In addition, RMP version 31 has been submitted as part of this application. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 20/09/2018 | 23/09/2019 | SmPC | The SmPC section 5.1 has been updated as follows: EXSCEL was a pragmatic cardiovascular (CV) outcome study in patients with type 2 diabetes and any level of CV risk. A total of 14,752 patients were randomised 1:1 to either prolonged release exenatide 2 mg once weekly or placebo, added to the current usual care which could include SGLT2 inhibitors. Patients were followed as in routine clinical practice for a median of 38.7 months with a median treatment duration of 27.8 months. The primary safety (noninferiority) and efficacy (superiority) endpoint in EXSCEL was the time to first confirmed Major Adverse Cardiac Event (MACE): cardiovascular (CV) related death, nonfatal myocardial infarction (MI) or nonfatal stroke. All-cause mortality was the initial secondary endpoint assessed. Prolonged release exenatide did not increase the cardiovascular risk in patients with type 2 diabetes mellitus compared to placebo when added to current usual care (HR:0.91; 95% CI: 0.832, 1.004; P<0.001 for non- inferiority). The study, however, failed to show a statistically significant benefit with exenatide treatment with regards to CV events or CV-related death. The need for additional antihyperglycaemic medication was reduced by 33% with the prolonged-release exenatide group (exposure-adjusted incidence of 10.5 per 100 pt- year) compared to the placebo group (exposure-adjusted |

<div style=\"page-break-after: always\"></div>

|          |                                                                                                                                                                                                                                                                                                   |            |            |                        | incidence of 15.7 per 100 pt-year). A reduction in HbA1c was observed over the course of the trial with an overall treatment difference of 0.53% (prolonged release exenatide vs. placebo). For more information, please refer to the Summary of Product Characteristics   |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0053  | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                        | 30/08/2018 | n/a        |                        |                                                                                                                                                                                                                                                                            |
| X/0048/G | This was an application for a group of variations. Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                | 28/06/2018 | 27/08/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                            |
| IB/0051  | B.II.g.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supporting data                                                                                                                                                                      | 23/05/2018 | n/a        |                        |                                                                                                                                                                                                                                                                            |
| IB/0049  | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                      | 15/03/2018 | n/a        |                        |                                                                                                                                                                                                                                                                            |
| II/0045  | Extension of Indication to include treatment in combination with basal insulin for Bydureon; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated based on the study D5553C00002 (Duration 7 study) which evaluated safety and efficacy of exenatide once weekly therapy | 12/10/2017 | 10/11/2017 | SmPC and PL            | Please refer to Scientific Discussion Bydureon-H-C-2020-II- 45                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                    | added to titrated basal insulin in patients with type 2 diabetes who have inadequate glycemic control on basal insulin with or without metformin. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor corrections in sections 4.8 and 5.1 of the SmPC. Furthermore, the consolidated RMP version 29 has been agreed. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                             |            |            |             |                                                                          |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------|
| PSUSA/9147/ 201703 | Periodic Safety Update EU Single assessment - exenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 26/10/2017 | n/a        |             | PRAC Recommendation - maintenance                                        |
| II/0041            | Extension of indication for Bydureon to include the add-on use of exenatide in combination with dapagliflozin to patients whose diabetes is not adequately controlled with metformin based on the study D5553C00003 (Duration 8 study); section 4.1 of the SmPC is updated in order to align the indication wording with more recently approved glucose-lowering agents. Section 5.1 of the SmPC is also updated with the results of study D5553C00003 (Duration 8 study). The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes in the SmPC and Package Leaflet and to update the Irish local representative information in the Package Leaflet. Furthermore, the consolidated RMP version 27 has been agreed. | 20/07/2017 | 24/08/2017 | SmPC and PL | Please refer to the scientific discussion Bydureon EMEA/H/C/002020/II/41 |

<div style=\"page-break-after: always\"></div>

|           | - Change(s) to therapeutic indication(s) - of a new therapeutic indication or of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |      | C.I.6.a Addition modification   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------|
| IG/0821   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28/07/2017 | 10/11/2017 | SmPC |                                 |
| IA/0044/G | application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor approved test procedure                                                                                                                | 05/05/2017 | n/a        |      | This was an changes to an       |
| II/0042   | Submission of the updated RMP version 25 following closure and final summary of Exenatide Pregnancy Registry (a prospective, observational study conducted in the United States that actively collected information on exposure to antidiabetic medication during pregnancy and the associated pregnancy outcomes in patients with Type 2 diabetes mellitus). Moreover, the MAH included additional minor updates to the RMP. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing | 21/04/2017 | n/a        |      |                                 |

<div style=\"page-break-after: always\"></div>

| IA/0043/G   | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                    | 03/03/2017   | n/a        |                    |                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0040/G   | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 16/12/2016   | n/a        |                    |                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0038     | Update of section 5.1 of the SmPC in order to include data from study 2993LAR-105: a randomized open- label, multicenter, comparator-controlled study to examine the effects of exenatide long-acting release on glucose control (HbA1c) and safety in subjects with type 2 diabetes mellitus managed with diet modification and exercise and/or oral anti-diabetic                                                                                                                                        | 10/11/2016   | 24/08/2017 | SmPC and Labelling | In the uncontrolled study extension of a clinical study in which prolonged-release exenatide 2 mg once weekly has been compared to immediate release exenatide 5 mcg given twice daily for 4 weeks followed by immediate release exenatide 10 mcg given twice daily, evaluable patients who switched from immediate release to prolonged-release exenatide at week 30 (n=121), achieved the same |

<div style=\"page-break-after: always\"></div>

|                    | medications (long-term extension). In addition, the MAH took the opportunity to bring the Labelling in line with the latest QRD template version 10. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                        |            |            |                           | improvement in HbA1c of 2.0% at week 52 compared to baseline as patients treated with prolonged-release exenatide. For all patients completing the uncontrolled study extension of 7 years (n=122 of 243 patients included in the extension phase), HbA1c gradually increased over time from week 52 onwards, but was still reduced compared to baseline after 7 years (-1.1%). Weight loss was sustained over 7 years in these patients.   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9147/ 201603 | Periodic Safety Update EU Single assessment - exenatide                                                                                                                                                                                                                                                                                                   | 27/10/2016 | n/a        |                           | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0039/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 03/08/2016 | n/a        |                           |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0035            | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                     | 03/03/2016 | n/a        |                           |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0036            | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                              | 23/02/2016 | n/a        |                           |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| R/0031             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                   | 17/12/2015 | 18/02/2016 | SmPC, Annex II, Labelling | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            | and PL   | Bydureon in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0034/G   | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.c.1.z - Change in immediate packaging of the AS - Other variation B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time | 18/12/2015 | n/a        |          |                                                                                                                                                        |
| PSUSA/9147/ | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/10/2015 | 16/12/2015 | SmPC     | Refer to Scientific conclusions and grounds recommending                                                                                               |

<div style=\"page-break-after: always\"></div>

| 201503      | exenatide                                                                                                                                                                                                                                                                                 |            |            |                 | the variation to terms of the Marketing Authorisation(s)' for PSUSA/9147/201503.                                                  |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------|
| IG/0633     | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                           | 09/12/2015 | n/a        |                 |                                                                                                                                   |
| IB/0032     | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                      | 04/12/2015 | n/a        |                 |                                                                                                                                   |
| IB/0030     | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                      | 22/06/2015 | n/a        |                 |                                                                                                                                   |
| IG/0522     | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                           | 12/03/2015 | n/a        |                 |                                                                                                                                   |
| PSUV/0024   | Periodic Safety Update                                                                                                                                                                                                                                                                    | 20/11/2014 | 19/01/2015 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0024. |
| IAIN/0027/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 19/12/2014 | 16/12/2015 | Annex II and PL |                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        |                                                                                                                                                  |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0026    | Transfer of Marketing Authorisation from Bristol- Myers Squibb/AstraZeneca EEIG to AstraZeneca AB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 12/09/2014 | 01/10/2014 | SmPC, Labelling and PL |                                                                                                                                                  |
| PSUV/0018 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/05/2014 | 31/07/2014 | SmPC and PL            | Please refer to Bydureon PSUV-18 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IA/0025/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph | 30/07/2014 | n/a        |                        |                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | the Ph. Eur. or national pharmacopoeia of a State - Change in test procedure for AS or material/reagent/intermediate - Minor to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        | of Member B.I.b.2.a starting changes   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------|
| II/0017/G | This was an application for a group of variations. Addition of a new excipient to the new presentation: sodium hydroxide. Addition of a new site responsible for the packaging of the drug product and new single container closure system (pre-filled pen presentation). Addition of an alternative manufacturing processspecific for the diluent in the new presentation in dual-chamber cartridge. Addition of an alternative pen injector device that contains the exenatide powder for injection and solvent for injection in a dual chamber cartridge, exclusive to the pre-filled pen presentation. To introduce an additional test for the excipient - carboxymethylcellulose sodium. Addition of an alternative specification on the finished cartridge of the pre-filled pen. | 24/07/2014 | 01/10/2014 | SmPC, Labelling and PL | Addition of a new immediate            |

<div style=\"page-break-after: always\"></div>

| (pre-filled pen presentation). Amendment to the current (version 20) to include prefilled pen presentation B.II.a.3.b.2 - Changes in (excipients) of the finished - Qualitative or quantitative excipients that may have safety, quality or efficacy B.II.b.1.f - Replacement manufacturing site for part manufacturing process manufacturing operation(s) release, batch control, and sterile medicinal products aseptically manufactured) immunological medicinal B.II.b.3.b - Change in the the finished or intermediate changes to a manufacturing significant impact on the of the medicinal product B.IV.1.c - Change of a measuring device - Addition or replacement an integrated part of the B.II.c.2.d - Change in test - Other changes to a test replacement or addition) B.II.d.1.c - Change in the   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | its corresponding test method B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                           |            |     | new specification   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------|
| IB/0023   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 08/07/2014 | n/a |                     |
| IB/0022/G | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 04/06/2014 | n/a |                     |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                 |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0019   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                     | 25/04/2014 | 31/07/2014 | SmPC and PL           | The scope of this variation was to update section 4.4 of the SmPC to update the safety information on acute pancreatitis following recommendations of an Art 5(3) procedure on GLP-1-based therapies and pancreatic safety. The Package Leaflet is updated accordingly. The benefit/risk balance of Bydureon remains unchanged.                                                                                                                     |
| IB/0020   | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                                                                                                                                                                                                                                                                                                                                        | 27/02/2014 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUV/0014 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/10/2013 | 08/01/2014 | SmPC and PL           | For further information please refer to: Bydureon-H-2020- Grounds-PSU-14-en.                                                                                                                                                                                                                                                                                                                                                                        |
| II/0013   | The scope of this variation was to update section 4.8 of the SmPC to include 'intestinal obstruction' and its frequency in the list of adverse reactions and to update the Package Leaflet accordingly. This variation was subsequent to the assessment of a signal for intestinal stenosis and a cumulative review of gastrointestinal stenosis and obstruction with the use of exenatide. The benefit/risk balance of Bydureon remains unchanged. C.I.z - Changes (Safety/Efficacy) of Human and | 18/12/2013 | 31/07/2014 | SmPC, Annex II and PL | The scope of this variation was to update section 4.8 of the SmPC to include 'intestinal obstruction' and its frequency in the list of adverse reactions and to update the Package Leaflet accordingly. This variation was subsequent to the assessment of a signal for intestinal stenosis and a cumulative review of gastrointestinal stenosis and obstruction with the use of exenatide. The benefit/risk balance of Bydureon remains unchanged. |

<div style=\"page-break-after: always\"></div>

| IA/0016/G   | for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 13/12/2013   | n/a        |                 | This was an application   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|---------------------------|
| IAIN/0015/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 08/11/2013   | 31/07/2014 | Annex II and PL |                           |
| IA/0012     | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                      | 06/09/2013   | n/a        |                 |                           |

<div style=\"page-break-after: always\"></div>

| IG/0301   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/07/2013   | n/a        |                        |                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------|
| IB/0009/G | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a | 28/06/2013   | n/a        |                        | Member State      |
| II/0008/G | This was an application for a group of variations. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with                                                            | 30/05/2013   | 08/01/2014 | SmPC, Labelling and PL | NO new additional |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0004/G   | This was an application for a group of variations. Update of sections 4.8 and 5.1 in order to include post-marketing experience of 'anaphylactic reactions, rash, pruritus, urticaria and angioedema', as a result of the assessment of PSUR 13, to update the SmPC with regard to pancreatitis reporting and to address a number of other minor editorial changes in these sections. In addition, the MAH took the opportunity to update annex II in line with the latest QRD template version 8.3. The Package Leaflet is updated accordingly. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   | 21/03/2013   | 26/07/2013   | SmPC, Annex II and PL   | The scope of these type II variations was to update section 4.8 of the SmPC regarding Bydureon post-marketing experience of 'anaphylactic reactions, rash, pruritus, urticaria and angioedema', which was requested as a result of the assessment of PSUR 13. Furthermore, the scope was to make the Bydureon SmPC consistent with the Byetta SmPC with respect to pancreatitis reporting and consequent revision of the frequency category in section 4.8 (table 2) of the SmPC for Bydureon. Additionally, a number of other minor editorial changes were proposed in section 4.8 (table 1) and 5.1 (table 4 and table 5). The MAH implemented frequency categories or the additional category 'not known' for 'anaphylactic reactions' , 'rash', 'pruritus', 'urticaria' and 'angioedema' and moved the information from table 2 (reflecting experience from Byetta) to table 1 (reflecting experience from Bydureon) in section 4.8 of the SmPC and changed the lay-out of table 1 and table 2 according to the lay-out of table 1 of Byetta. In order to assign consistency between Byetta and Bydureon, the MAH proposed to change the frequency category for 'acute pancreatitis' in table 2 for Bydureon (reflecting experience from Byetta) in section 4.8 from 'uncommon' to 'rare' to be consistent with Byetta, on which the experience with acute pancreatitis with exenatide is based on, which was accepted by the CHMP. Further minor editorial changes proposed by the MAH in section 4.8 and 5.1 of the SmPC were endorsed by the CHMP. The benefit-risk for Bydureon remains favourable.   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0007      | Transfer of Market Authorisation from Eli Lilly                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18/02/2013   | 13/03/2013   | SmPC,                   | Transfer of the Marketing Authorisation to Bristol-Myers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | Nederland B.V. to Bristol-Myers Squibb/AstraZeneca EEIG. Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                            |            |            | Labelling and PL   | Squibb/AstraZeneca EEIG.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|----------------------------|
| IB/0006   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                               | 12/12/2012 | 13/03/2013 | SmPC               |                            |
| IB/0005   | B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                              | 14/11/2012 | n/a        |                    |                            |
| IG/0189   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                                                                                                                                                                                                   | 22/06/2012 | n/a        |                    |                            |
| IB/0001   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                               | 24/08/2011 | n/a        |                    |                            |
| IA/0002/G | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 11/08/2011 | n/a        |                    |                            |

<div style=\"page-break-after: always\"></div>

| the pharmacovigilance system   |
|--------------------------------|